Clinical Trial Update: Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). [Phase 3]

View source ↗

Summary

Phase 3 HySSAS trial evaluating hydroxychloroquine as a steroid-sparing therapy for pulmonary sarcoidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Sarcoidosis

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: University of Milano Bicocca | Conditions: Pulmonary Sarcoidosis | Phase 3 | Status: COMPLETED